Your browser doesn't support javascript.
loading
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi, Karim; Azad, Arun A; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C C; Voog, Eric; Jones, Robert J; Shore, Neal D; Dunshee, Curtis; Zschäbitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G; Di Santo, Nicola; Laird, A Douglas; Zohren, Fabian; Agarwal, Neeraj.
Afiliação
  • Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. karim.fizazi@gustaveroussy.fr.
  • Azad AA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
  • Carles J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fay AP; PUCRS School of Medicine, Porto Alegre, Brazil.
  • De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
  • Joung JY; National Cancer Center, Goyang, Republic of Korea.
  • Fong PCC; Auckland City Hospital, Auckland, New Zealand.
  • Voog E; University of Auckland, Auckland, New Zealand.
  • Jones RJ; Clinique Victor Hugo Centre Jean Bernard, Le Mans, France.
  • Shore ND; School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Dunshee C; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
  • Zschäbitz S; Arizona Urology Specialists, Tucson, AZ, USA.
  • Oldenburg J; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Ye D; Akershus University Hospital (Ahus), Lørenskog, Norway.
  • Lin X; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Healy CG; Pfizer Inc., La Jolla, CA, USA.
  • Di Santo N; Pfizer Inc., Collegeville, PA, USA.
  • Laird AD; Pfizer Inc., Durham, NC, USA.
  • Zohren F; Pfizer Inc., La Jolla, CA, USA.
  • Agarwal N; Pfizer Inc., New York, NY, USA.
Nat Med ; 30(5): 1505, 2024 May.
Article em En | MEDLINE | ID: mdl-38297094

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article